Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Muñoz-Couselo

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature researchTeresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2024
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injuryMar Riveiro-Barciela, Ana Barreira-Díaz, María-Teresa Salcedo, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 27, 2025
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)Pablo Ayala-de Miguel, Eva Muñoz-Couselo, Lourdes Gutiérrez-Sanz, et al.
NPJ Precision Oncology|July 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumabHelen Gogas, Shruthi Ravimohan, Antara Datta, et al.
Melanoma Research|September 15, 2015
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitorsMaria Gonzalez-Cao, Clara Mayo-de-Las-Casas, Miguel A Molina-Vila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through ProteogenomicsMaria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, et al.
The Journal of Experimental Medicine|June 9, 2018
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapiesAzad Saei, Marta Palafox, Touati Benoukraf, et al.
Frontiers in Oncology|April 5, 2024
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposureAnna Spreafico, Eva Muñoz Couselo, Anja Irmisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 CriteriaIgnacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature researchTeresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2024
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injuryMar Riveiro-Barciela, Ana Barreira-Díaz, María-Teresa Salcedo, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 27, 2025
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)Pablo Ayala-de Miguel, Eva Muñoz-Couselo, Lourdes Gutiérrez-Sanz, et al.
NPJ Precision Oncology|July 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumabHelen Gogas, Shruthi Ravimohan, Antara Datta, et al.
Melanoma Research|September 15, 2015
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitorsMaria Gonzalez-Cao, Clara Mayo-de-Las-Casas, Miguel A Molina-Vila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through ProteogenomicsMaria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, et al.
The Journal of Experimental Medicine|June 9, 2018
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapiesAzad Saei, Marta Palafox, Touati Benoukraf, et al.
Frontiers in Oncology|April 5, 2024
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposureAnna Spreafico, Eva Muñoz Couselo, Anja Irmisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 CriteriaIgnacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
Pageof 8